Regulatory
Dietary Supplements and Cardiovascular Health: Getting to the Heart of Omega-3 Claims
January 28th 2011While a wealth of scientific evidence demonstrates the beneficial role of long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for general wellness and multiple health conditions, the strongest evidence by far is in the area of cardiovascular health.
EFSA and Probiotics: Gut Response
January 28th 2011Editor’s Note: On December 2, the European Food Safety Authority (EFSA; Parma, Italy) held a meeting in Amsterdam with the intention of clarifying its process of reviewing Article 13 and Article 14 health claims, specifically those concerning gut and immune health. The probiotics community was well represented at the meeting, which was led by members of EFSA’s Dietetic Products, Nutrition, and Allergies (NDA) panel. Below are reflections from the meeting from representatives of probiotics specialist Danisco A/S (Denmark).
Dietary Supplement Marketing and the EU: Putting the Squeeze on Health Claims
January 28th 2011It is a difficult time to be operating in the European functional foods space. Ingredient suppliers in particular have endured months of nervous anticipation as they wait for European Food Safety Authority (EFSA; Parma, Italy) opinions on health claims being assessed under the Nutrition and Health Claims Regulation (EU Regulation EC/1924/2006).
FDA Should Be Empowered to Request Evidence for Structure-Function Claims, GAO Suggests
January 18th 2011Claiming that FDA is currently hampered in evaluating “potentially false or misleading structure/function claims,” the U.S. Government Accountability Office (GAO) has recommended in a new report that the agency be given the power to request evidence of substantiation from companies.
Supreme Court Mulls Testimony About AERs in Zicam Case
January 12th 2011Should drug and supplement companies be required to alert investors whenever any adverse-event report (AERs) over a product arises-in case an AER is predictive of a larger problem with the product that could devalue shareholder stocks?